A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer

<div>BRCA1/2 mutations and OS by cancer type. (a) Breast cancer. (b) Ovarian cancer. (c) Pancreatic cancer. Clifton (1), neoadjuvant group; Clifton (2), adjuvant group; OS, overall survival; and HR, hazard ratio.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer 

Figure 2 | A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer 